MedTrace Logo

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

NCT03206931 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-09-16

No results posted yet for this study

Summary

Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Conditions

  • Solid Tumors Harboring NTRK Fusion

Interventions

DRUG

Selitrectinib (BAY2731954)

Selitrectinib is administered as capsules or liquid formulation.

Sponsors & Collaborators

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206931 on ClinicalTrials.gov